Filing Flows › Senti Biosciences Holdings (SNTI) › Recalls, complaints & regulation

Senti Biosciences Holdings (SNTI): clinical trials

Senti Biosciences Holdings (SNTI) beyond its filings: 1 active clinical trial.

Senti Biosciences Holdings' latest quarter

Senti Biosciences Holdings, Q2 2026: revenue $17K, net loss $12.8M, operating cash flow −$14.2M. The chart follows the revenue to costs, profit and cash.

Questions

How many clinical trials does Senti Biosciences Holdings have?

1 active study on ClinicalTrials.gov, 0 in phase 3.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.